Pirtobrutinib (LOXO-305) is a novel non-covalent inhibitor with a high selectivity for BTK described in an ongoing study of CLL patients previously treated with covalent BTK inhibitors [101]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.